Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

KPTIBullishCorporate Developmentsnews

High materiality8/10

Karyopharm to file sNDA for selinexor-ruxolitinib in myelofibrosis

Jul 30, 2026, 4:10 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Accelerated-approval potential and near-term regulatory milestones typically drive upside for KPTI if the FDA signals openness to SVR35; however, execution risk and OS confirmatory data remain key risks.

AI summary

What happened, with direct paths to the underlying reporting

Karyopharm plans an August 2026 sNDA submission seeking accelerated approval of selinexor with ruxolitinib for myelofibrosis, based on SVR35 data and early OS signals from SENTRY. A Priority Review could yield a six-month PDUFA date if the FDA accepts SVR35 as a surrogate endpoint, potentially making this the first approved MF combination therapy.

Karyopharm plans sNDA submission for selinexor plus ruxolitinib in MF by August 2026.
They will request Priority Review; PDUFA target date about six months after filing.
SVR35 used as RLSE; SENTRY OS signals to verify clinical benefit.
If approved, this could become the first approved MF combo therapy.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Karyopharm to file sNDA for selinexor-ruxolitinib in myelofibrosis

Karyopharm's SENTRY Trial Shows Promising Results for Myelofibrosis Treatment

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results